Inovio Pharmaceuticals, Inc. (INO): Simon X Benito , director of Inovio Pharmaceuticals, Inc. sold 6,250 shares on May 18, 2016. The Insider selling transaction was reported by the company on May 18, 2016 to the Securities and Exchange Commission. The shares were sold at $10.37 per share for a total value of $64,818.75 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 18, 2016, Morton Collins (director) purchased 68,400 shares at $9.49 per share price.On Sep 30, 2015, Niranjan Sardesai (COO) purchased 4,000 shares at $5.50 per share price.Also, On Aug 17, 2015, Simon X Benito (director) purchased 6,000 shares at $7.21 per share price.On Apr 13, 2015, Angel Cabrera (director) purchased 8,000 shares at $9.53 per share price.
Shares of Inovio Pharmaceuticals Inc (INO) ended Thursday, May 19, 2016 session in red amid volatile trading. The shares closed down -0.21 points or -2.04% at $10.1 with 9,52,626 shares getting traded. Post opening the session at $10.34, the shares hit an intraday low of $9.98 and an intraday high of $10.4 and the price vacillated in this range throughout the day. The company has a market cap of $738,280 M and the number of outstanding shares has been calculated to be 73,09,70,00,000 shares. The 52-week high of Inovio Pharmaceuticals Inc is $11.69 and the 52-week low is $4.5.
Company has been under the radar of several Street Analysts.Inovio Pharmaceuticals Inc is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 13 from a previous price target of $19 . The Rating was issued on Mar 15, 2016.
Inovio Pharmaceuticals Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31 2014 Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers prostate cancer breast/lung/pancreatic cancer hepatitis C virus (HCV) hepatitis B virus (HBV) HIV influenza and Ebola. With its immunotherapy platform consisting of SynCon products as well as its CELLECTRA electroporation delivery technology Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio’s immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.